ArticleCureus2025
The External Validation of SACrA (Sex, Albumin, Creatinine, and APACHE II) Score for Predicting Nonemergent Renal Replacement Therapy Initiation: A Retrospective Study Based on the Medical Information Mart for Intensive Care - Version IV Database.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective The SACrA [sex, albumin, creatinine, and Acute Physiology and Chronic Health Evaluation II (APACHE II)] score was developed to objectively predict nonemergent renal replacement therapy (RRT) initiation. This study aimed to validate the SACrA score externally by using the Medical Information Mart for Intensive Care - Version IV (MIMIC-IV) database. Methods We conducted a retrospective cohort study using the MIMIC-IV database. Patients admitted to the ICU with a total hospital stay of ≥7 days were included, whereas those with chronic kidney disease grade 5, end-stage renal disease, post-kidney transplant status, or urgent RRT indications were excluded from this study. The primary outcomes were the discrimination [area under the curve (AUC)] and calibration of the SACrA score to predict nonemergent RRT initiation, defined as blood urea nitrogen (BUN) ≥112 mg/dL or oliguria lasting >72 hours. Results Among the 16,360 ICU patients who met the inclusion criteria, 14,226 were analyzed after applying the exclusion criteria. Of them, 658 (4.6%) met the criteria for nonemergent RRT initiation, and 351 patients (2.5%) actually received RRT. The SACrA score showed good discrimination, with an AUC of 0.81 in the primary dataset and similar performance across multiple imputed datasets (AUCs ranging from 0.81 to 0.82). Calibration plots indicated that the SACrA score was well-calibrated, with a slope of 1.002 and an intercept of 0.007. Decision curve analysis indicated the potential clinical utility of this score in guiding nonemergent RRT initiation. Conclusions The SACrA score is a reliable tool for predicting nonemergent RRT initiation in critically ill patients. Although it accurately identifies high-risk patients, further randomized controlled trials (RCTs) are required to determine whether targeted interventions based on SACrA scores can improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.